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Abstract
BEHAVIORAL PHENOTYPING OF THE DISCRIMINATIVE STIMULUS
PROPERTIES OF THE ATYPICAL ANTIPSYCHOTIC DRUG CLOZAPINE IN
129S2/HSV MICE
By Kevin A. Webster, B.S.
A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University.
Virginia Commonwealth University, 2012
Major Director:
Joseph H. Porter PhD., Professor of Psychology, Department of Psychology

The 129S2 inbred mouse strain is often used as a background strain in the
production of genetically altered mice (i.e. knockout and transgenic mice). It is important
to establish the behavioral phenotype of wild-type mice before making comparisons to
genetically altered mice. Also, those comparisons can assist in the evaluation and
interpretation of the in vivo effects of drugs. The drug discrimination assay measures the
subjective effects of drugs and provides a measure of underlying neuropharmacological
mechanisms responsible for the discriminative stimulus properties of drugs. The present
study established the atypical antipsychotic drug clozapine as a discriminative stimulus in
male 129S2 inbred mice and compared clozapine‘s discriminative stimulus properties in
129S2 mice to C57BL/6 and DBA/2 inbred mice. By comparing the discriminative
stimulus properties between inbred strains of mice we hope to obtain a fuller picture of
the underlying neuropharmacological mechanisms of antipsychotic drugs.
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Behavioral Phenotyping of the Discriminative Stimulus Properties of the Atypical
Antipsychotic Drug Clozapine in 129S2/HSV mice.
Schizophrenia is a severe and complex psychological disorder. It has been
historically reported to affect approximately 1% of the world's population and onset
typically occurs during late adolescence or early young adulthood in the early to mid-20s.
The prognosis for a patient that develops schizophrenia is grim as most carry the disease
with them their entire life. The early 1950s saw a revolution in the treatment of
schizophrenic patients with the introduction of antipsychotic drugs; however, the disease
has eluded a cure due in part to a murky etiology. While studies have shown a clear
genetic component for schizophrenia, monozygotic twins only have a 50% concurrence
rate for the disease implying that other factors such as neurodevelopmental events and/or
environmental influences also play a strong role in the etiology of schizophrenia (Brown,
2011).

Etymology of schizophrenia

The term schizophrenia was first coined by Swiss physician Paul Eugen Bleuler at
the 1908 meeting of the German Psychiatric Association in Berlin (Fusar-Poli & Politi,
2008). Bleuler introduced the term as more precise nomenclature for a series of
symptoms that at the time was called dementia praecox, or young dementia. The term
dementia praecox had been popularized by Emile Kraepelin, but Bleuler believed that the
symptoms he had noticed were not a form of ―dementia‖ but something more.
Schizophrenia, Bleuler felt, was a more accurate word for the disorganization of thoughts
that was prevalent with patients suffering from the disorder. However Beuler's choice has
`
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led to modern day confusion among a majority of lay and medical professionals alike.
The Grecian roots for the word skhizein and phren translate to ―split mind‖. Many
unfamiliar with the field associate the word with someone who is suffering from a
disorder now known as dissociative identity disorder, or split personality.

Symptomatology

The DSM-IV-TR (APA, 2000) characterizes schizophrenia with five main
symptoms: delusions, hallucinations, disorganized speech, grossly abnormal psychomotor
behavior, and negative symptoms. These symptoms can cause social skills and relations
to deteriorate in the patient and may be noticed by trouble at work or with other
interpersonal relationships. In childhood and adolescent patients the inability to acquire
fully functional social skills can be an early indicator for schizophrenia. Other symptoms
have been identified, however, and symptoms of schizophrenia are often classified in one
of three categories: positive symptoms, negative symptoms, or cognitive deficits (APA,
2000).

Positive symptoms are characterized by a manifestation of behaviors not present
in unaffected patients. Positive symptoms are the more recognizable manifestation of
schizophrenia and when schizophrenics are portrayed in the media and popular culture
the positive symptoms are most often emphasized. Hallucinations and delusions are the
archetypal positive symptoms; however, disorganized thought, incoherent speech, and
disorganized thinking also inhabit this class. Hallucinations are often auditory (e.g. the
schizophrenic hears voices whispering constantly in their ear), but visual hallucinations
2
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have also been reported, especially in children (David et al., 2011). Delusions are one of
the other common positive symptoms of schizophrenia and can appear in different forms.
Delusions of grandeur may lead the affected to believe that they are the reincarnation of a
great leader, figure from history, or some form of powerful and omnipotent being.
Delusions of persecution manifest with thoughts that someone is watching the
schizophrenic constantly, be it a secret government agent, a shadowy organization, or
even beings of a religious/supernatural nature. Disorganized thinking is considered
another positive symptom of schizophrenia, and often manifests itself through
disorganized speech sometimes referred to as ―word salad‖. Noam Chomsky's famous
phrase ―Colorless green ideas sleep furiously‖ exemplifies the concept of word salad,
while the sentence follows proper syntax for sentence construction it holds no logical
weight. Finally other strange motor anomalies are classified as positive symptoms in the
schizophrenic, including tracing patterns in the air or on a surface, holding a single pose
for extended periods of time, or random frantic movement (APA 2000).

Negative symptoms of schizophrenia are not as prevalent in popular depictions of
the disorder. This set of symptoms is characterized by a lack of behavior in the
schizophrenic that is present in the unaffected population. Poverty of speech (alogia) and
flat affect (a lack of emotional response), are two stereotypical negative symptoms.
Apathy and avolition are two symptoms that define a patient‘s lack of motivation,
avolition being distinct from apathy by a schizophrenic‘s desire to do a task but lacking
the motivation to begin or initiate it. Asociality, an inability to empathize with other
people, is one of the symptoms of schizophrenia that leads to a rapid deterioration of
3
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social, familial, and work life for those who develop the disease. Finally anhedonia is
used to describe the lack of pleasure schizophrenics feel when doing activities that
normally bring them joy.

There has been some debate in the psychiatric community as to whether cognitive
deficits should be included as a symptom of schizophrenia. Studies have shown that there
is a correlation between decreased cognitive function and the schizophrenic's functional
prognosis, yet the variety of factors that determine cognitive functioning leave the line
between the two murky (Green, Kern, Braff, & Mintz, 2000). There is a strong body of
research and reviews calling for cognitive impairment to be included in the Diagnostics
and Statistics Manual Edition Five, the North American standard for classifying
psychological disorders. Two of the main arguments for this distinction would be to raise
awareness of cognitive dysfunction (Keefe & Fenton, 2007) hopefully leading to better
treatment methods, and that the inclusion of cognitive deficits would help to distinguish
schizophrenia from mood disorders (Keefe, 2008). However opponents of the inclusion
of cognitive dysfunction claim that there is simply too much variability in that data to
clearly associate specific cognitive symptoms with schizophrenia (Gold 2008).

Incidence and Prevalence

While what causes schizophrenia is still clouded in mystery, hypotheses range
from genetic vulnerability to seasonality of birth. By studying the incidence, how many
new cases are reported in a given time span, and prevalence, the proportion of the general
population that have the disorder, researchers can start to identify areas to focus their
4
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work to help develop treatment methods and discover the underlying cause of the
disorder. Onset occurs most commonly in young adulthood and while those affected will
struggle with the disease for the rest of their lives, recovery of a functional life is
obtainable for many schizophrenics. Unfortunately, the burden of psychosis is too much
for some to handle and suicide among schizophrenics is not uncommon, especially
among those dealing with their first episode of the disorder (Caldwell & Gottesman,
1990).

While traditional estimates of the prevalence of schizophrenia have been reported
to be 1% worldwide, recent research has suggested that this may be overestimating the
number of people who have the disorder. In a review article of 158 studies incidence of
schizophrenia was calculated to be 15.2 new cases annually per 100,000 people, less than
.02% of the population. However this was the median rate of incidence with 10% and
90% quartiles ranging from 7.7 to 43.0 new cases annually per 100,000 people with
studies more frequently reporting incidence rates above the median range (McGrath et al.,
2004). However even at its highest estimate .04% of the population becoming
schizophrenics is a relatively low rate, but with a life time struggle ahead for the majority
of those diagnosed it is reasonable to see how prevalence rates can begin to compound.

Another review article analyzing prevalence of schizophrenia in 188 studies
determined that the lifetime morbid risk, the number of people who will develop
schizophrenia in their life time, was 7.2 per 1000 people, putting medial percentage of
schizophrenia in the population at 0.72%, lower than the historically reported value of
1.0% prevalence. While median values for point, period, and life time prevalence varied
5
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they were not significantly different from each other (Saha, Chant, Welham, & McGrath,
2005).

These studies on the incidence, how many new cases are reported in a given time
span, and prevalence, the proportion of the general population that have the disorder, also
reveal interesting demographic data on who in the population develops schizophrenia.
Men have a higher incidence of the disorder, approximately 1.4 men will develop
schizophrenia for every woman that does (McGarth et al. 2004). Interestingly there is no
statistical difference in the prevalence of schizophrenia between the sexes, a median ratio
of 1.11 men have this disorder for each woman that has it, possibly hinting at a difference
in the course of the disease (Saha et al., 2005). Data were inconclusive or non-significant
for differences between urban and rural dwelling schizophrenics. The review also reports
a significantly increased incidence and prevalence of schizophrenia in migrant
populations, median incidence in the migrant population is 4.6 new cases for every new
case in native born population, and median prevalence reveals a ratio of 1.84 migrant
schizophrenics for every native born schizophrenic (McGrath et al., 2004). The
prevalence of schizophrenia also seems to be lower in less developed countries, with
median rates of 2.62 per 1000 people. While rates in emerging economic countries are
higher (median rates 4.69 per 1000 people) than developed countries (median 3.30 per
1000 people) the two are not significantly different (Saha et al., 2005).

Suicide among schizophrenics is another hidden problem with the disorder. While
estimates for the prevalence of suicide have been reported as high as 10% (Phillips,
Yang, Li, & Li, 2004) and 19.56% in affected patients 18-30 (Osborn, Levy, Nazareth, &
6
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King, 2008) a life time risk of approximately 5% is the most accepted figure (Hor &
Taylor, 2010). Unsurprisingly some of the major risk factors for suicide in schizophrenics
is similar to those in the general population including mood disorder, recent loss, drug
misuse, and previous attempts at suicide (Hawton, Sutton, Haw, Sinclair, & Deeks,
2005). More recently, a literature review also identified several illness related factors
strongly associated with schizophrenia including depression, signs of physical illness, and
increased positive symptoms of schizophrenia specifically hallucinations and delusions
(Hor & Taylor, 2010).

Causes

What causes schizophrenia has been a point of interest ever since the discovery of
the affliction. High concurrence rates in monozygotic twins as well as higher concurrence
rates for closer relatives point to a genetic component of the disorder. However,
fascinating case studies such as the Genain Quadruplets, four identical twins who all
developed schizophrenia but in different severities (Mirsky & Quinn, 1988), show that
development and environment still play a major role in a patient‘s prognosis.

Twin studies play an integral role in studying the genetic and environmental
influences of schizophrenia. Monozygotic twins show a 45-60% concurrence rate for
developing schizophrenia, compared to the 10-15% for dizygotic twins (Brown, 2011).
Combined with the steady concurrence for the population worldwide it would seem that
schizophrenia would be a prime candidate to be considered a genetic disorder. Most twin
studies seem to support this idea; Borgwardt et al. (2010) reported that between
7
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concordant and discordant monozygotic twins those with schizophrenia had similar
decreases in grey matter volume, a trait common among all schizophrenics. A metaanalysis of twin studies reports that heredity (how much variation between subjects can
be attributed to genomic differences) accounts for 73-90% of the variance of whether or
not a patient develops schizophrenia while environment only accounts for 3%-19%
(Sullivan, Kendler, & Neale, 2003); however, Brown et al. (2011) state that this estimate
of the effect of environment is not completely correct and may downplay the influence of
the environment.

Nonetheless, genetics remains an integral part of the question of who will develop
schizophrenia and how severe it will be. With the advances in genetic screening and
molecular genetics the search for specific genetic markers has swept the research
community into a fervor. The vast number of potential subjects and vast amount of
genetic variation in the world should make it easy to find a common genetic marker for
many common psychological disorders; however, this ―common disease, common
variant‖ hypothesis has failed to produce convincing evidence that there is a single
marker for schizophrenia (Gershon, Alliey-Rodriguez, & Liu, 2011) or other common
psychological disorders. Still, genetic models and markers exist for schizophrenia, the
leader being Disrupted in Schizophrenia 1 (DISC1). The DISC1 gene encodes for a
protein of the same name and appears to be important for many aspects of neuronal
development. Translocation of this gene is what causes its disruption, and it is this
disruption that is thought to cause predisposition to schizophrenia and other ―common‖
psychological diseases. Transgenic animal models of DISC1 have shown phenotypic
8
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effects similar to those seen in human subjects in terms of cognitive and behavioral
functioning as well as brain anatomy (Johnstone et al., 2011).

Schizophrenia seems to not only affect cognitive and social functioning but
produces changes in brain structure as well. One important focus is the relationship
between brain abnormalities and schizophrenia; do the abnormalities predispose someone
to schizophrenia or does schizophrenia cause the brain to deteriorate as the patient
continues to live? Studies have shown that magnetic resonance imaging (MRI) of firstepisode schizophrenic patients shows similar brain abnormalities, specifically: enlarged
ventricles, loss of overall brain volume, and decreased hippocampal mass (Vita, De Peri,
Silenzi, & Dieci, 2006). While Vita et al. failed to show significant reduction in amygdala
volume in first-episode patients, other studies (Lawrie & Abukmeil, 1998; Wright et al.,
2000) have shown significant reductions in amygdala volume in chronic schizophrenic
patients. Although more research needs to be done in the field, these findings suggest that
some aspects of abnormal brain morphology are inherit to those who are predisposed to
schizophrenia, while other changes in brain morphology may appear as a result of the
disease. The idea of brain abnormalities in predisposed twins, regardless of actual
affliction, are presented in a study that showed a phenotypic reduction in brain size across
discordant twins affected with schizophrenia (van Haren et al., 2004) and decreases in
grey matter volume across discordant twins (Borgwardt et al., 2010).

An interesting correlation has been drawn between prevalence of schizophrenia
and the season of a patient‘s birth. A review article looking at 86 studies of birth season
of schizophrenics identified a correlation between those born in the Winter-Spring,
9
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specifically January-April, and an increased prevalence of schizophrenia (Torrey, Miller,
Rawlings, & Yolken, 1997). Not only are birth rates of those who will develop
schizophrenia higher in those months but this review also found there was a decrease in
the number of births of schizophrenics in the opposing seasons (summer-fall). The
winter-spring excess of schizophrenics also occurs in the southern hemisphere, even
though the months for these seasons are reverse from the northern hemisphere. What
causes this increased incidence of schizophrenia for the winter-spring months is still
unclear. While theories range from seasonal variations of infection and external toxins to
procreation habits of parents of schizophrenics, research for each hypothesis seems to be
contradictive or nonsignificant. The more likely story, as with most things, is that there
are multiple factors at play, which will exacerbate other factors eventually leading to the
excess birth rates during these months (Torrey et al., 1997).

Exposure to specific viral infections has also been suspected as a possible risk
factor for schizophrenia. Prenatal infection of many diseases has been shown to cause
brain abnormalities, mental retardation, and learning disabilities (Brown & Derkits, 2010)
making investigation for schizophrenia a relatively easy choice. Recently research in this
area has shifted from studying prevalence in the wake of infection epidemics to birthcohort longitudinal studies. Influenza, toxoplasma gondii, herpes simplex type 2, and
certain cytokines have been shown to increase the prevalence of schizophrenia as
compared to nonaffected controls. Again, the question is raised whether each disease has
a specific causal link between infection and development of schizophrenia or are there
more common factors involved, i.e. does prenatal infection simply lead to a more
10
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vulnerable fetus? Preclinical studies looking at animal models of prenatal infection have
shown that pregnant mice infected with influenza have shown abnormal behavior in a
variety of assays commonly used as animal models of schizophrenic behaviors (Shi,
Fatemi, Sidwell, & Patterson, 2003) similar results have been shown with agents that
mimic viral infection without actually causing an infection (Brown & Derkits, 2010).
Gene-environment interactions may also play a role in infectious disease and
schizophrenia though no clear causal link has been identified.
Today many researchers believe that schizophrenia has a ‗two-hit‘ model of
infection. First proposed in Bayer (1999) this ‗two-hit‘ model suggests that neither
genetic vulnerability nor environmental factors alone are enough to bring about the
disease. A genetic predisposition or prenatal environmental event disrupts neural
development in some way, the ‗first-hit‘, which establishes an increased vulnerability for
a second hit later in life (Maynard et al. 2001). The idea that both genetics and
environment play a summative role has been reported in clinical data and presented in
animal models. Further examination of this ‗two hit‘ model in animals can also
differentiate the influence of different genes of interest in human schizophrenia. If two
genes produce different behavioral phenotypes under the same environmental influence
then they may have different importance for schizophrenia.

Treatment History

While Kraepelin and Bleuler pioneered the definition of schizophrenia, historical
medical texts and accounts can trace disorders that have symptoms similar to
11
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schizophrenia across multiple cultures and time periods. Even as far back as 1500 B.C.E.
the Book of Hearts, part of an ancient Egyptian medical scroll the Ebers Papyrus,
describes cognitive dysfunction similar to that of schizophrenia (Kyziridis, 2005). Most
of these early descriptions draw the cause of mental anguish back to some supernatural
cause, possession by a daemon or the wrath of a displeased god, and treatments ranged
from prayer and sacrifices, an attempt to appease the wronged god, to more dangerous
methods such as drilling holes in the patients head to exorcise the trapped daemon.
Supernatural influences maintained a firm grasp on the origin and explanation of
mental disorders throughout the middle ages. This did not completely hinder the
development of diagnosis and treatment of mental disorder though, as early medical
scholars and physicians began to distinguish mental disease from bodily disease as early
as the 6th century C.E. (Kyziridis, 2005). By the end of the middle ages mental disorders,
usually under the broad term insanity, were a distinct class of disease. However treatment
was far from what it is today. In the early 14th century the first insane asylums began to
appear in Europe but most asylums at this time were simply places to hold patients, not
treat them. The ―treatments‖ that were practiced in these asylums were often crude,
ineffective, and dangerous; ranging from being restrained in a chair for days on end to
more farfetched procedures like trepanning, an ancient surgical technique where a hole
was drilled in the patients head to exorcise the daemons trapped within. By the late 1700s
a movement had started, as William Battie noted in Treatise on Madness ―Madness,
therefore, like most other morbid cases, rejects all general methods, e.g. bleeding,
blisters, caustics, rough cathartics, the gumms and faetid anti-hysterics, opium, mineral
waters, cold bathing and vomits‖ (Morris, 2008). What had become standard practice for
12
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treatment of disease, mental or otherwise, was not working and a new protocol was
needed. In the late 18th century pioneers of psychiatric treatment had begun to emerge
and called for better management of the mentally ill. Phillipe Pinel, William Tuke, and
others began to open reform asylums that used more humane methods to manage the
mentally ill. The success of these methods caught on quickly and by the mid-19th century
asylums began to celebrate institutions free of the restraints and barbaric treatments of the
past (Kyziridis, 2005)
In the early 1950s a monumental breakthrough in the management of
schizophrenia came with the first pharmacological treatment- chlorpromazine. Originally
developed for use as an anesthetic during surgery, French surgeon Henri Laborit was
among the first to notice how the drug produced tranquilizing effects without sedation;
and he began to postulate about its antipsychotic application (Stip, 2002). While these
behavioral effects were being noticed the underlying pharmacological mechanism was
still a complete mystery to the early prescribers of neuroleptics. It would take over ten
years before results were published showing that blockade of dopamine receptors was the
main mechanism of action for what became the first generation antipsychotics (Carlsson
& Lindqvist, 1963). Chlorpromazine is classified as a typical or first generation,
antipsychotic and shares this nomenclature with other early antipsychotics such as
haloperidol and thioridazine. As with chlorpromazine, these drugs‘ main mechanism of
action is through blockade of dopamine receptors, specifically D2 and D3 receptors
(Tajima, Fernandez, Lopez-Ibor, Carrasco, & Diaz-Marsa, 2009). While these first
generation antipsychotics represented a major advancement for the treatment and
management of schizophrenia, they were not without their drawbacks. In general, typical
13
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antipsychotic drugs work well to reduce the positive symptoms of schizophrenia, but they
are marginally effective, at best, at alleviating negative symptoms and cognitive deficits
that are common in schizophrenics (Tajima et al., 2009). These drugs also have a long list
of side effects, the most prevalent among them being extrapyramidal motor side effects
(EPS), which are classified as Parkinsonian like tremors and other small, repetitive motor
movements. These EPS effects were thought to be predictive of clinical efficacy in the
early days of treatment- the stronger or more pronounced the EPS the more effective the
drug was thought to be. This theory turned out to not only be wrong but dangerous, since
strong EPS became a desired quality when dosing early generation antipsychotics
(Weiden, 2007).
In the same decade that chlorpromazine came on the market another drug that
would again revolutionize the treatment of schizophrenia came out of the laboratory
setting. Clozapine, sometimes hailed as the gold standard of ―atypical‖ antipsychotics,
was first synthesized in 1958 by a small Swiss laboratory (Wander Laboratories). While
early testing of clozapine was meet with mixed results, including a lack of motor side
effects, in 1966 Hanns Hippius continued the clinical trials started by Wander just 7 years
earlier and found that clozapine effectively treated psychotic symptoms without the
expected EPS effects (Ramachandraiah, Subramaniam, & Tancer, 2009). Clozapine‘s
efficacy at alleviating the positive and negative symptoms, combined with its lack of EPS
effects, helped clozapine gain momentum until misfortune struck in the mid-1970s. In
1975 Griffith and Saameli reported in Lancet that sixteen Finnish patients who had been
given clozapine had developed agranulocytosis, an acute drop in white blood cell count,
resulting in nine deaths (Griffith & Saameli, 1975). This caused the Finnish government
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to quickly pull clozapine from the market, and other European countries soon followed
suit. Although it had been pulled from most markets, research on this new antipsychotic
continued. In 1988 a study was published showing that patients who did not respond well
to typical antipsychotic drugs showed a significant improvement after treatment with
clozapine. Patients who had been given clozapine treatment displayed significant
improvements in Clinical Global Impressions, Brief Psychiatric Rating Scale, Nurses'
Observation Scale for Inpatient Evaluation - all scales that measure the severity of a
patient‘s symptoms or quality of life (Kane, Honigfeld, Singer, & Meltzer, 1988). A
number of clozapine ―clones‖, drugs with similar binding profiles or chemical structures,
began to appear in the 1990s. Drugs such as olanzapine, quetiapine, and risperidone were
more efficacious and caused less side effects, especially EPS, than their typical
predecessors; although, except for clozapine, none of the newer drugs seemed to be more
efficacious than any other (Ramachandraiah et al., 2009). While clozapine is still
reserved for use in patients resistant to other forms of treatment, its superior efficacy for
treating the symptoms of schizophrenia and decreased motor side effects leaves it as one
of the most effective treatments for schizophrenia.
Clozapine
Clozapine began a new era of pharmacological treatment in schizophrenia. The
drugs that would later fill out the ranks of the atypical antipsychotics mimic, in some
way, its structure and receptor binding profile. While classification of antipsychotics is
often characterized by presence or severity of EPS effects (Meltzer, 2000), most atypical
antipsychotics share a mechanism of action that differs from the mechanism of most
15
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typical antipsychotics. Most typical antipsychotics work through antagonism of D2/D3
receptors with strong receptor binding affinity (Creese, Burt, & Snyder, 1976). This
dopamine receptor antagonism is also thought to be the pharmacological source of many
of the side effects in first generation drugs (Meltzer & Stahl, 1976). Atypical
antipsychotics bind to dopamine D2 and D3 receptors, although their affinity for D2 and
D3 receptors is lowered as compared typical antipsychotics, while the ratio of binding to
5-HT2 receptor subtypes relative to dopamine binding is greater than in typical
antipsychotics (Meltzer, Matsubara, & Lee, 1989). Specifically it is thought that the
inverse agonist action of 5-HT2A in combination with weak D2/D3 antagonism as well as
5-HT2A antagonism causes atypical antipsychotics to be more efficacious and more
tolerable than typical antipsychotic drugs. (Meltzer & Massey, 2011).
Behavioral Phenotyping
Behavioral phenotyping is the study of how genetic differences between
organisms affect the organisms‘ behavior. While integral to finding behavioral
differences between genetically altered animals and their background control strains, it
can also be used to examine differences between inbreed strains of the same species.
Behavioral phenotyping can also be used to draw similarities from studies using different
strains of the same species. Although the C57/BL6 mouse has become the ―poster child‖
for rodents, specifically mice, used in behavioral research it is not perfect for all
behavioral models. Testing done with other popular strains, including DBA/2 and 129
substrains (129S, 129T, 129P) can draw correlates to other research done with C57BL/6
mice. The C57BL/6 and 129 strains are commonly used as background strains when
producing knockout mice. Examining how each of these strains performs on a specific
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task, as well as the B6129 hybrid strain, can give important insights into the behavior of
any knockout mice produced using C57 and 129 inbred strains as the parent or
background strain by providing a behavioral baseline free of genetic manipulation.
Review articles have examined a large number of inbred mouse strain using a variety of
different behavioral measures, however the battery of behavioral assays and strains or
genes of interest change from area to area (Crawley et al., 1997; Hossain, Wong, &
Simpson, 2004). Also, behavior is highly susceptible to subtle environmental changes
from lab to lab leading some to question the validity of some results found through
behavioral phenotyping (Crabbe, Wahlsten, & Dudek, 1999).
Behavioral phenotyping of inbred strains can also highlight the importance of
genetics, metabolism, and receptor expression on behavior. In particular drug
discrimination studies with clozapine using different inbred strains and knockout animals
can lead to insights about the underlying receptor mechanisms that account for the
discriminative stimulus properties of a drug. Clozapine discrimination has already been
established in C57BL/6 mice and DBA/2 mice. Both strains were able to acquire the
discrimination with a training dose of 2.5 mg/kg and ED50 values for clozapine were
similar in both strains, (ED50 = 1.19 mg/kg (95% CI = 1.09-1.30 mg/kg) for C57BL/6
(Philibin et al., 2009) and ED50 = 1.30 (95% CI = 1.178-1.443 mg/kg) for DBA/2 (Porter,
Walentiny, Philibin, Vunck, & Crabbe, 2008)). While antagonism of α1 and 5-HT2
receptors are important in the discriminative stimulus properties of clozapine in C57BL/6
mice, none of the tested selective antagonists substituted for clozapine in the DBA/2
strain, implying a compound cue in the DBA/2 strain (Porter et al., 2008) (see Table 1).
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Drug Discrimination with Antipsychotic Drugs
Drug discrimination is a preclinical assay where animals are trained to make a
specific operant response depending on the presession treatment condition the animal
received. Drug discrimination with antipsychotics has been established in a variety of
species including pigeons (Hoenicke, Vanecek, & Woods, 1992), rodents (Goudie, Smith,
Taylor, Taylor, & Tricklebank, 1998; Philibin, Prus, Pehrson, & Porter, 2005), and nonhuman primates (Carey & Bergman, 1997). Drug discrimination studies with
antipsychotics have also been shown to be resistant to small methodological changes, as
response to training drugs and test drugs are fairly consistent despite differences in presession injection times, schedule of reinforcement, type of reinforcer, and route of
injections across studies (Porter & Prus, 2009).
Drug discrimination is used to determine which neurochemical mechanisms play
an important role in the discriminative properties of the training drug. The idea that
action at a specific neurotransmitter receptor can produce discernible changes in how the
animal feels (i.e. subjective effects) is central to the drug discrimination procedure. Drug
discrimination allows researchers to explore the pharmacological effects of drugs in vivo
and can uncover important behavioral effects that molecular assays are unable to detect.
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Table 1
Comparison of selective ligands tested in C57BL/6 and DBA/2 animals in a clozapine
drug discrimination assay.
Shows substitution testing of selective ligands tested in both C57 and DBA inbreed
strains of mice trained to discriminate 2.5mg/kg clozapine from vehicle. FULL: Full
substitution with percent drug lever responding ≥ 80%, PARTIAL: Partial with
substitution percent drug lever responding ≥ 60%, NO: No substitution with percent drug
lever Selective Ligands Tested
C57BL/6 mice DBA/2 mice
Ritanserin (5-HT2A/2B/2C antagonist)

FULL

NO

Scopolamine (muscarinic antagonist)

PARTIAL

PARTIAL

Prazosin (α1 adrenergic antagonist)

FULL

NO

Pyrilamine (H1 antagonist)

NO

NO

Amphetamine (dopamine agonist)

NO

NO

responding < 60%. Data presented is compiled from (Philibin et al., 2009; Porter et al.,
2008)

19

`

Nearly a decade after chlorpromazine was introduced the first drug discrimination
studies using antipsychotics began to appear. Chlorpromazine was used as a training drug
for many of these early studies and while training doses, types of reward, and subsequent
results varied between these early studies, the studies showed that antipsychotic drugs
could be established as discriminative stimuli in this procedure. Stewart (1962) using 4.0
mg/kg chlorpromazine versus vehicle, showed that stimulus control could be established
and maintained in a three-compartment shock avoidance chamber. Twelve years later
chlorpromazine (1.0 mg/kg) versus vehicle was again established in rats using a twolever operant task, in which the animals received a food reinforcer for correct responses
and a shock for incorrect responses (Barry, Steenberg, Manian, & Buckley, 1974).
Compared to atypical antipsychotics most typical antipsychotics have a relatively
limited binding profile. High affinity at the dopamine D2 receptor family is one of the
main similarities of receptor binding in typical antipsychotics. Atypical antipsychotics
have a higher affinity at 5-HT2A receptors relative to D2 receptors. D2 receptor blockade
is thought to be important for the therapeutic action of both typical and atypical
antipsychotics (Seeman & Tallerico, 1999), while action at 5-HT2A receptors is believed
to be responsible for the lowered risk of EPS seen in atypical antipsychotics as the ratio
of D2 and 5-HT2A binding is higher in atypical antipsychotics while maintaining D2
receptor affinity is similar (Meltzer, 2002). Although binding data can give us insight to
binding affinity of specific receptor subtypes, it does not tell us about agonism or
antagonism; thus, knowing the binding of a drug alone can only give us clues to the
mechanisms of action of a drug.
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Clozapine is the prototypical atypical antipsychotic, which makes it a prime target
for drug discrimination studies. With a superior clinical efficacy and diverse binding
profile understanding the discriminative stimulus properties of clozapine may provide
important information about the psychopharmacology of schizophrenia and its treatment.
While clozapine‘s discriminative cue has been established in different animal models
what mediates its cue differs from species to species and even within strain. The
discriminative cue in pigeons is mediated by 5-HT2A/2C antagonism (Hoenicke et al.,
1992). While antagonism of 5-HT receptors plays a role in clozapine‘s discriminative
stimulus for C57BL/6 mice, 5-HT2A along with α-1 adrenoceptors are the main
mechanisms responsible for clozapine‘s cue in that mouse strain (Philibin et al., 2005;
Philibin et al., 2009) but not in DBA/2 mice who did not demonstrate substitution for
any selected ligands (Porter et al., 2008). Interestingly multiple studies have identified
cholinergic antagonism of M1 receptors as the primary cue mediating clozapine‘s
discriminative cue in Wistar and Sprague-Dawley rats (Goudie et al., 1998; Kelley &
Porter, 1997; Nielsen, 1988) .
Mutant Mice – Knock Out and Transgenic mice
With the undeniable evidence that schizophrenia has a genetic component to it,
the development of mutant animal models has allowed for the study of the genetic
variability in both the treatment and prevention of schizophrenia by allowing how
specific genetic manipulations change development of schizophrenic like symptoms and
what drugs can be used to treat these behavioral abnormalities. While no one single gene
has been identified as causing schizophrenia, a number of candidate genes have been
identified and it is likely that a number of genes play a small, summative role in the
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development of the disorder (Picchioni & Murray, 2007). Mutant animal models have
also helped in preclinical trials for new treatment drugs by giving researchers animals
that have cognitive deficits or neurological morphology closer to what is seen in humans
with schizophrenia.
The ability to genetically manipulate the mouse genome to delete genes of interest
was done first by a trio of cancer researchers Mario R. Capecchi, Martin J. Evans, and
Oliver Smithies, in 1989 for which they were awarded the 2007 Nobel Prize in medicine
(Beckman, 2008). Since then an entire industry for the production and distribution of
genetically altered mice has been developed, placing specific models of behavior and the
ability to study genes of interest in the hands of researchers. Two genes in particular have
garnered great attention from the research community in the study and understanding of
schizophrenia: NGR1, and DISC1.
DISC1 (disrupted in schizophrenia 1) was originally found in a large Scottish
family in 1970 and has since been shown to play a role in the development of multiple
mood disorders, including schizophrenia (Blackwood et al., 2001). Researchers found
that DISC1 knockout animals display animal analogs of schizophrenic behavior (Hikida
et al., 2007) as well as changes in brain morphology similar to those seen in human
patients (Ellison-Wright, Glahn, Laird, Thelen, & Bullmore, 2008). Bolstered by
similarities in both human and animal studies DISC1 is one of the genetic targets of
schizophrenia that has received a large deal of attention from the research community.
NRG1 (neuregulin 1) is a gene that in humans is heavily involved with
neurodevelopment, particularly in aspects that have been tied to the brain abnormalities
seen in schizophrenia specifically serotonin and dopamine receptor expression and
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monoamine transporters (Mei & Xiong, 2008). While complete knockout of the NRG1
gene is lethal (animals that are homozygous knockouts cannot survive without this gene),
+/- heterozygous knockouts have increased levels of dopamine receptors in the prefrontal
cortex (Stefansson et al., 2002). Research has shown a strong positive correlation with
polymorphisms of NRG1 and susceptibility to schizophrenia (Li, Collier, & He 2006) and
while this research helps to unify a number of different leads on the cause of
schizophrenia, including dysregulation of multiple neurotransmitter systems, it is far from
the final answer to a genetic cause of schizophrenia.

Rationale
Clozapine is the prototypical second generation (atypical) antipsychotic. Its
unique and diverse binding profile paired with its clinical superiority over other atypical
and typical antipsychotics could lead to better understanding of the neuropharmacological
mechanisms important for the treatment of schizophrenia and how to improve the quality
of life for those afflicted through management of the disease. With alleviation of both
positive and negative symptoms in schizophrenia, a severely reduced presence of EPS,
and the ability to alleviate symptoms in patients who have shown resistance to other
antipsychotics clozapine‘s clinical superiority as an antipsychotic is clear.
Drug discrimination is a powerful behavioral assay that allows researchers to
examine the in vivo subjective effects of a drug and to determine what receptor
mechanisms in vivo mediate a drug‘s discriminative stimulus properties. Examining the
difference in discriminative cues between species and strains can help to explain how
differences in brain morphology, receptor availability, metabolism, and other factors can
23

`

change the discriminative cue of a drug and may help lead to more specific treatments for
those who have schizophrenia.
The present study used drug discrimination to examine mechanisms of action of
clozapine in 129S2/HSv mice and how these mechanisms differ from C57BL/6 and
DBA/2 inbred mouse strains. Clozapine is a second generation, atypical antipsychotic
drug developed in 1958. To date no drug discrimination studies have used clozapine as a
training drug in the 129S2 strain. As such, this research is an original preclinical study in
the effort to investigate the discriminative stimulus properties of clozapine in 129S2
inbred mice.
There are four objective of this study: first, to establish clozapine as a
discriminative stimulus in a standard two-lever drug discrimination procedure in
129S2/HSv mice; second, to test typical and atypical antipsychotic drugs to see if they
share any discriminative stimulus properties with clozapine; third to test selective ligands
to determine the underlying pharmacological mechanisms mediating the discriminative
stimulus properties of clozapine in 129S2/HSv mice; and fourth, to compare these
findings to previous studies that used C57BL/6 and DBA2 mice to determine how
clozapine‘s discriminative cue compares between these three inbred strains of mice.
Methods
Subjects
Seventeen adult male 129S2/SvHsd inbred mice weighing between 20-30 g
(Harlan Laboratories, Indianapolis, IN) were used for this study. Mice were individually
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housed in clear plastic cages (18 x 29 x 13 cm) with fitted steel wire tops and cornhusk
bedding. They were moved daily (6 to 7 days each week) from a temperature controlled
vivarium (22-24° C) under a 12h light/dark cycle (0600/1800 hours) to the laboratory
where testing occurred. All research was conducted in accordance with the Institutional
Animal Care and use Committee at Virginia Commonwealth University, which approved
all procedures. After a one week habituation period animals were food restricted and
maintained at 85-90% free feeding body weight on standard rodent chow (Harlan Teklad
Lab Diets, Teklad LM-485). Water was available ad libitum in home cages.
Apparatus
Drug discrimination experiments were conducted in six standard computerinterfaced mouse operant conditioning chambers (Model ENV-307A; Med Associates,
St. Albans, VT, USA), with two retractable levers positioned on the left and right
positions equidistantly (8 cm apart) on the front wall. The levers extended 0.8 cm into the
chamber and were positioned 2.5 cm above a grid floor constructed of parallel stainless
steel bars, measuring 0.3 cm in diameter. A recessed well in which a liquid dipper would
deliver 0.02 ml of sweetened milk (by volume 150 ml sugar, 150 ml powdered non-fat
milk, and 500 ml water) was positioned between the two levers-. The inner area of the
test chamber measured 15 x 11.5 x 17.5 cm and was surrounded by an aluminum chassis
box with a Plexiglas back wall, 2 aluminum side walls, and a single Plexiglas door. Test
chambers were housed in a sound attenuated cubicle (Model ENV-022; Med Associates).
Experimental events and data collection during these experiments were controlled by
Med-PC for Windows software (Med Associates Inc. version 1.0). Unless otherwise
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noted the dipper that delivered the milk was raised and available to the animal in the
operant chamber for three seconds before descending back into the trough where the
sweetened milk liquid reinforcer was kept.
Drugs
Clozapine (gift from Novartis, Hanover, NJ, USA), haloperidol, scopolamine and
pyrilamine (Sigma, St. Louis, MO, USA), olanzapine (gift from Eli Lilly, Indianapolis,
Indiana, USA), ritanserin (Research Biochemicals International, Natick, Mississippi,
USA), iloperidone (gift from HY Meltzer), aripiprazole ( and M100907 (gift from
Lundbeck, Copenhagen, Denmark) were dissolved in distilled water with two to three
drops of lactic acid and pH balanced with sodium hydroxide (all drugs had a pH balance
close to 7.0). Chlorpromazine, amphetamine, prazosin (Sigma), thioridazine (Novartis),
and ziprasidone (ziprasidone mesylate, Roerig, Division of Pfizer, New York, USA) were
dissolved in deionized water and pH balanced with sodium hydroxide (all drugs had a pH
balance close to 7.0). Drugs were administrated subcutaneously (s.c.) at a volume of 10
ml/kg body weight with a 30-min presession injection time. All doses refer to the salt
(HCl) form of the drugs.
Procedures
Magazine training. The mice were placed in an operant chamber for fifteen
minutes. No levers were extended and mice were given access to a sweetened milk liquid
reinforcer every 10 sec; the reinforcer would be available for 5 sec. During magazine
training reinforcers were presented regardless of the animals‘ behavior.
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FR training. After 3 days of magazine training, mice began single lever fixed
ratio (FR) training. Only the vehicle lever was presented and animals were given access
to a liquid reinforcer every time they pressed the lever, i.e. a FR 1 schedule of
reinforcement. Training sessions (15 min) were conducted daily, six days a week. The FR
requirement was gradually increased over 18 sessions until a stable response rate at FR
10 was achieved. On average the mice achieved FR 10 after 12.2 days (Range 11-18).
Errorless training. Once all mice had reached a stable response rate at FR 10
they began errorless vehicle training. Animals received an injection of vehicle (deionized
water with 3 drops of lactic acid (~.01 ml) per 50 ml deionized water, pH balanced to 7.0
with sodium hydroxide). Test sessions were 15 minutes long with only the vehicle lever
available. All animals received 6 days of errorless vehicle training before moving to
errorless drug training. During errorless drug training, the mice were given an injection of
the training dose of clozapine and placed in the operant chamber for a 15 minute session.
Only the drug lever was presented and animals were again under the FR 10 schedule of
reinforcement. The drug and vehicle lever positions were counterbalanced between
groups to control for olfactory cues (Extance and Goudie 1981). In order to provide a
comparison to clozapine drug discrimination in C57BL/6 mice (Philibin et al. 2005), a
2.5 mg/kg training dose of clozapine was initially used; however this dose was
abandoned after 8 sessions due to continued, severe rate suppressant effects in the mice.
The training dose was lowered to 1.25 mg/kg and response rates for all animals increased
to acceptable levels. Errorless clozapine training continued for an average of 9.7 days
(range 8-15 days).
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Two lever acquisition training. All animals were placed on a double alternation
injection schedule with two days of vehicle followed by two days of clozapine and
repeated (VEH, VEH, CLZ, CLZ, VEH, VEH etc.). Both levers were present during this
stage of the procedure; however, only responses on the condition-appropriate lever were
reinforced. Any response made on the opposite lever reset the FR 10 counter to 0. In
order for a mouse to pass a training day it had to meet three criteria: (1) complete the first
FR on the condition-appropriate lever, (2) at least 80% of total responses made were on
the condition appropriate lever, and (3) at least ten responses per minute were made.
Animals were required to meet training criteria for 5 of 6 days to pass the acquisition
phase of the study. All animals meet training criteria in an average of 21.2 days (range 6
to 33 days).
Testing. Once animals meet the training criteria, generalization and substitution
testing began. Drug testing was conducted approximately two times per week with at
least two training days in between. In order to be eligible for testing mice were required
to pass both a clozapine and vehicle training day consecutively; however, they could be
passed in either order. Before the clozapine generalization curve and subsequent dose
response curves were conducted, clozapine and vehicle control tests had to be passed.
During these control tests animals received an injection of 1.25 mg/kg clozapine or
vehicle and both levers were reinforced on the FR 10 schedule (switching levers prior to
completing the FR 10 requirement reset the counter for the opposite lever). To pass a
control test animals were required to meet the training criteria (correct first FR, 80% or
greater condition-appropriate responding, and response rates equal to or greater than 10
responses per minute). If an animal failed a control test, it was placed back on the double
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alternation training schedule and the next time it was available to test it would be retested
at that control point.
Data analysis. The number of lever presses on the drug lever divided by the total
number of lever presses (% Drug Lever Responding), the average number of responses
per minute, and the lever that the animal pressed ten times consecutively (First Fixed
Ratio) were recorded for each session. ED50 values were calculated for each drug dose
effect curve that fully substituted (average percent drug lever responding >80%) for the
training drug clozapine. ED50 values were calculated using the least squares method of
linear regression with the linear portion of the dose effect curve. A repeated measures
analysis of variance (ANOVA) comparing mean response rates for each dose was
performed for each drug (GB-STAT software; Dynamic Microsystems, Inc., Silver
Spring, MD). Significant ANOVAs were followed by a Dunnett‘s post-hoc test (p <
0.05). Animals were required to receive one reinforcer or have response rates equal to or
greater than 2.0 responses per minute to have percent drug lever responding (%DLR)
included in the group data.

Results
Acquisition
The results of the acquisition training for the mice successfully trained to
discriminate 1.25 mg/kg clozapine from vehicle are shown in Figure 1. Seventeen of the
nineteen mice reached training criteria in an average of 21.2 days (SEM + 8.5) with a
range of 6-33 days. One mouse became ill during single lever training and another animal
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failed to develop tolerance to the rate suppressant effects of clozapine and both were
removed from the study.
Clozapine Generalization Curve
Mean percent drug lever responding (+ SEM) and mean responses per minute (+
SEM) for the clozapine generalization curve (1.25 mg/kg training dose) are shown in
Figure 2. Generalization testing yielded an ED50 = 0.5026 mg/kg (95% C. I. 0.3812 –
0.6627 mg/kg). Full generalization to clozapine‘s discriminative cue was attained at 1.25
mg/kg, 1.77 mg/kg, and 2.5 mg/kg with a significant suppression (F7, 105 = 6.86, p < .001)
of response rates at the 2.5 mg/kg dose (the %DLR data were not included for 1 mouse
whose RPM fell below 2.0 RPM. Four mice were tested at a dose of 5.0 mg/kg clozapine;
however, this dose was abandoned as responding was completely suppressed for all 4
animals.
Clozapine Time Course
Time course data shown in Figure 3 demonstrated that the 1.25 mg/kg training
dose of clozapine produced full responding on the drug-paired lever only at the 30 minute
post s.c. injection time point. Partial clozapine substitution was seen at 15 minutes post
s.c. injection (average drug lever responding = 66.1%). At 60 minutes post s.c. injection
drug-lever responding dropped to 39.1% and at 120 minutes post injection drug-lever
responding decreased to vehicle-level responding with only 6.2% drug-lever responding.
Mean response rates were stable across all time points.
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Figure 1. Acquisition of Clozapine Discrimination
Acquisition of two-lever drug discrimination is shown for 1.25 mg/kg clozapine training
dose. Mean percent drug lever responses ( + SEM) are presented separately for drug
injections (closed circles) and vehicle injections (open circles). The dashed line at 80%
indicates drug-appropriate responding and the dashed line at 20% indicated vehicleappropriate responding. As the mice met the training criteria, they were removed from
the curves (the numbers in parenthesis indicate the number of remaining mice).
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Figure 2. Clozapine Generalization Curve
Mean percent drug lever responding (+ SEM) and mean responses per minute (+ SEM)
are shown for the atypical antipsychotic clozapine generalization curve (1.25 mg/kg
clozapine training dose) in a two-lever drug discrimination procedure. The dashed line at
80% drug lever responding (DLR) indicates full generalization to the training drug. Prior
to generalization testing, control test sessions were conducted with both clozapine (1.25
mg/kg) and vehicle. The data for mice with response rates lower than two responses per
minute were not included in the %DLR data. For the response rate data, significant
differences from vehicle are indicated by asterisks (* P < 0.05, **P < 0.01)

32

`

% DLR
RSP/MIN

100
80
60
40

**

**

20
0

**
CLZVEH

0

15

30

60

70
60
50
40
30
20
10
0

Responses Per Minute

%Drug Lever Responding

Time Course (N=8)

120

Time (min)
Figure 3. Clozapine Discrimination Time Course
Time course data are shown for 0, 15, 30, 60, and 120 min presession s.c. injection times
for the 1.25 mg/kg training dose of clozapine. For percent drug lever responding,
significant differences from the presession injection time (30 min) are indicated by
asterisks (** P<.001). There were no significant differences for response rates.
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Olanzapine Substitution
The atypical antipsychotic olanzapine produced full substitution for clozapine
(Figure 4) at 0.25 mg/kg (95.6% DLR) with a significant reduction in response rates at
both the 0.125 and 0.25 mg/kg doses (F 5,30 = 37.11, P <.001) Generalization testing with
olanzapine yielded an ED50 = 0.03774 mg/kg (95% CI 0.02553 – 0.05580 mg/kg).
Aripiprazole Substitution
The atypical antipsychotic aripiprazole (Figure 5) did not substitute for clozapine
at any of the tested doses (1.25 – 10.0 mg/kg) and maximum %DLR was seen at the 5.0
mg/kg dose (44.5% DLR). All doses of aripiprazole produced significant rate suppression
(F4,20 = 6.14, p = .002).
Ziprasidone Substitution
The atypical antipsychotic ziprasidone (Figure 6) did not produce substitution to
clozapine at any of the tested doses (0.25 – 8.0 mg/kg) with maximum clozapineappropriate responding at 8.0 mg/kg (47.9% DLR). Ziprasidone did not produce any
significant changes in response rates (F6,30 = 1.57, p = .191)
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Figure 4. Olanzapine Substitution Curve
Mean percent drug lever responding (+ SEM) and mean responses per minute (+ SEM)
are shown for the atypical antipsychotic olanzapine substitution curve. All other details
are the same as Figure 2.
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Figure 5 Aripiprazole Substitution Curve
Mean percentage drug-lever responding (+ SEM) and mean responses per minute (+
SEM) are shown for the atypical antipsychotic aripiprazole substitution curve. All other
details are the same as Figure 2.
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Figure 6 Ziprasidone Substitution Curve
Mean percentage drug-lever responding (+ SEM) and mean responses per minute (+
SEM) are shown for the atypical antipsychotic ziprasidone substitution curve. All other
details are the same as Figure 2.
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Iloperidone Substitution
The atypical antipsychotic iloperidone (Figure 7) produced full substitution at 0.2
mg/kg (84.6% DLR) and high partial substitution at 0.4 mg/kg (75.8% DLR).
Generalization testing revealed an ED50 = 0.0947 mg/kg (95% CI = 0.0608 – 0.1456
mg/kg). While both 0.2 and 0.4 mg/kg doses produced significant rate suppression as
compared to vehicle (F5,35 = 27.23, p <.001), the effects at 0.4 mg/kg were stronger as
only 3 of the 7 animals had response rates over 2.0 RPM.
Haloperidol Substitution
The typical antipsychotic haloperidol did not fully substitute for clozapine (see
Figure 8) at any of the tested doses. Partial substitution was seen at 0.2 mg/kg (66.0%
DLR) and 0.4 mg/kg (66.4% DLR) doses of haloperidol. Rates were significantly
suppressed at by the 0.1, 0.2 and 0.4 mg/kg doses (F(5,245) = 1944.6, p < .001)
Chlorpromazine Substitution
The typical antipsychotic chlorpromazine (Figure 9) produced partial substitution
at 0.25 mg/kg (72.5% DLR), but no substitution at 0.125 or 0.5 mg/kg. The 0.25mg/kg
dose produced a significant suppression of response rates (F3,24 = 6.56, p = .003). Three
mice were tested at 1.0 mg/kg, but responding was completely suppressed so testing of
that dose was abandoned.
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Figure 7 Iloperidone Substitution Curve
Mean percentage drug-lever responding (+ SEM) and mean responses per minute (+
SEM) are shown for the atypical antipsychotic iloperidone substitution curve. All other
details are the same as Figure 2.
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Figure 8. Haloperidol Substitution Curve
Mean percent drug-lever responding (+ SEM) and mean responses per minute (+ SEM)
are shown for the typical antipsychotic haloperidol substitution curve. All other details
are the same as Figure 2
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Figure 9 Chlorpromazine Substitution Curve
Mean percentage drug-lever responding (+ SEM) and mean responses per minute (+
SEM) are shown for the typical antipsychotic chlorpromazine substitution curve. All
other details are the same as Figure 2.
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Thioridazine Substitution
The typical antipsychotic thioridazine (Figure 10) produced full substitution for
clozapine at 16.0 mg/kg (93.7% DLR) and generalization testing revealed an ED50 = 2.71
mg/kg (95% CI 1.65 - 4.46 mg/kg). The 8.0 and 16.0 mg/kg doses produced a small, but
significant suppression of response rates as compared to vehicle (F4,20 = 5.21, p = .005)
Pyrilamine Substitution
The histaminergic H1 antagonist pyrilamine (Figure 11) did not substitute for
clozapine at any of the tested doses (5.0 mg/kg – 28.3 mg/kg) never generating more than
16.8% drug-lever responding. Response rates were significantly reduced by the 28.3
mg/kg dose of pyrilamine (F 4,20 = 6.84, p = .001). Four animals were tested at 40.0
mg/kg pyrilamine however all animals were completely rate suppressed and testing at this
dose was abandoned.
Prazosin Substitution
The adrenergic α1 antagonist prazosin (Figure 12) fully substituted for clozapine
at the 10.0 mg/kg dose (83.4% DLR). Generalization testing yielded an ED50 = 1.1427
mg/kg (95% CI 0.70669 – 1.84784 mg/kg). Response rates were significantly reduced at
1.0, 3.0, and 10.0 mg/kg doses, as compared to vehicle (F6,42 = 11.63, p < .001).
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Figure 10 Thioridizine Substitution Curve
Mean percentage drug-lever responding (+ SEM) and mean responses per minute (+
SEM) are shown for the typical antipsychotic thioridazine substitution curve. All other
details are the same as Figure 2.
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Figure 11. Pyrilamine Substitution Curve
Mean percent drug-lever responding (+ SEM) and mean responses per minute (+ SEM)
are shown for the histaminergic (H1) antagonist pyrilamine substitution curve. All other
details are the same as Figure 2.
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Figure 12. Prazosin Substitution Curve
Mean percentage drug-lever responding (+ SEM) and mean responses per minute (+
SEM) are shown for the adrenergic α1 antagonist prazosin substitution curve. All other
details are the same as Figure 2.
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Scopolamine Substitution
The cholinergic muscarinic antagonist scopolamine (Figure 13) did not fully
substitute for clozapine; however, partial substitution was achieved at 8.0 mg/kg (68.0%
DLR). Significant rate suppression was seen at the 8.0 mg/kg dose (F5,35 = 4.55, p =
.003).
Amphetamine Substitution
The dopamine agonist amphetamine (Figure 14) did not substitute for clozapine at
any of the tested doses (0.25 – 2.0 mg/kg) with maximum clozapine-lever responding
reaching 20.53%. All doses produced significant rate suppression (F4,20 = 16.18, p <
.001) as compared to vehicle rates of response.
Ritanserin Substitution
The 5-HT2 antagonist ritanserin (Figure 15) did not substitute for clozapine at any
of the tested doses (1.0 – 16.0 mg/kg) with maximum clozapine lever responding
reaching 57.4%. Ritanserin did not produce any significant changes in response rates.
M100907 Substitution
The selective 5-HT2A antagonist M100907 (Figure 16) did not produce full
substitution for clozapine, although partial substitution was evident at the 3.0 and 5.6
mg/kg doses (69.1% DLR and 69.3% DLR, respectively). M100907 did not produce any
significant changes in response rates (F5,30 = 1.60, p =.190). 10.0 mg/kg M100907 was
tested in three animals but all were completely rate suppressed and testing at this dose
was abandoned.
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Figure 13 Scopolamine Substitution Curve
Mean percentage drug-lever responding (+ SEM) and mean responses per minute (+
SEM) are shown for the cholinergic muscarinic antagonist scoplamine substitution curve.
All other details are the same as Figure 2.
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Figure 14 Amphetamine Substitution Curve
Mean percentage drug-lever responding (+ SEM) and mean responses per minute (+
SEM) are shown for the dopamine agonist amphetamine substitution curve. All other
details are the same as Figure 2.
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Figure 15 Ritanserin Substitution Curve
Mean percentage drug-lever responding (+ SEM) and mean responses per minute (+
SEM) are shown for the 5-HT2 antagonist ritanserin substitution curve. All other details
are the same as Figure 2.
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Figure 16 M100-907 Substitution Curve
Mean percentage drug-lever responding (+ SEM) and mean responses per minute (+
SEM) are shown for the 5-HT2A antagonist M100907 substitution curve. All other details
are the same as Figure 2.

50

`

Discussion
Clozapine as a discriminative stimulus in 129S2/SvHsd mice
The current study demonstrated that clozapine can successfully be trained in the
129S2/SvHsd inbred mouse strain, continuing to expand on the data characterizing the
robust discriminative stimulus properties of clozapine, and how differences in genotype
and receptor expression can affect this cue. Clozapine‘s discriminative stimulus has been
established in several species of animals; including rats (Kelley & Porter, 1997; Millan et
al., 1999; Prus, Philibin, Pehrson, & Porter, 2005), pigeons (Hoenicke et al., 1992),
squirrel monkeys (Carey & Bergman, 1997), C57BL/6 inbred mice (Philibin et al., 2005;
Philibin et al., 2009) and DBA/2 inbred mice (Porter et al., 2008). While 129S2 mice
readily acquired the discriminative stimulus cue of clozapine, the average number of
training sessions for an animal to successfully pass 5 of 6 training days was significantly
longer than for C57 and DBA mice. Also the 129 mice did not initially develop tolerance
to 2.5 mg/kg of clozapine (used as the training dose in C57BL/6 and DBA/2 mice)
requiring the training dose to be lowered to 1.25 mg/kg.
Clozapine Tolerance
The first and most surprising behavioral difference seen in 129S2 mice was the
delayed development of tolerance to clozapine‘s rate suppressant effects. 129S2 mice did
not initially develop tolerance to 2.5 mg/kg clozapine, showing complete rate suppression
after 8 days of chronic administration. Although clozapine (as well as other antipsychotic
drugs) is known to have rate suppressant effects, tolerance to the suppressant effects of
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clozapine develops relatively rapidly after chronic administration (Varvel, Vann, Wise,
Philibin, & Porter, 2002). After a one-week washout period 1.25 mg/kg clozapine was
administered and the 129S2 mice were able to develop tolerance to the rate suppressant
effects of clozapine at this dose. Interestingly, when mice were tested with 2.5 mg/kg
clozapine in the clozapine generalization curve rate suppressant effects had somewhat
recovered, although response rates were still significantly less than vehicle rates (see
figure 2). This shows that the 129S2 inbred strain was able to develop some tolerance to
the rate suppressant effects of clozapine, but at a delayed rate.
Differences in how mouse strains metabolize clozapine could help to explain
these differences in development of tolerance. P450 cytochrome is a family of
endogenous enzymes that is the largest contributor of drug metabolism and bioactivation
(Guengerich, 2008). Examining differences in enzyme expression between mouse strains
could help to explain the differences between the 129, C57, and DBA inbred mouse
strains. Clozapine is mainly metabolized by the liver enzyme CYP1A2 while CYP2C19,
CYP2D6 and CYP3A4 play a lesser role in its metabolism (Urichuk, Prior, Dursun, &
Baker, 2008). Examination of liver enzyme expression in 5 inbred mouse strains,
C57BL/6 and 129/SvJ included, found no significant difference between strains in
expression or activity of cytochrome P450 enzyme family, including phenacetin Odeethylation which was used as a marker for CYP1A2 activity (Löfgren, Hagbjörk,
Ekman, Fransson-Steen, & Terelius, 2004). The lack of differences in the metabolizing
enzymes for clozapine should yield similar time courses between C57BL/6 and 129S2.
However, the time course for 1.25 mg/kg clozapine in 129S2 mice (see figure 3) showed
that the mice only fully substituted at the 30 minute presession injection time (the
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injection time the animals were trained at). By 60 minutes enough of the drug had left the
animal‘s system that drug lever responding was significantly reduced. This stands in
contrast to clozapine‘s time course in C57BL/6 mice that showed clozapine-like
responding at 15, 30, and 60 minutes post injection time (Philibin et al., 2005). These
data suggest that differences in metabolism of clozapine cannot be used to explain the
reduced tolerance to clozapine seen in the 129S2 inbred mouse strain.
5HT Antagonism
While it is not the only factor that differentiates atypical from typical
antipsychotic drugs, atypical antipsychotics possess a higher ratio of 5-HT2A binding to
DA2 binding as compared to typical antipsychotics with the exception of aripiprazole
(Meltzer et al., 1989) (see table 2) and amisulpride (Schoemaker et al., 1997) . Of the
atypical antipsychotics tested in the present study olanzapine and iloperidone engendered
clozapine-like responding while ziprasidone did not. Antagonism at 5-HT receptors has
been shown to be important for clozapine‘s discriminative cue in pigeons (Hoenicke et
al., 1992) and in C57BL/6 mice (Philibin et al., 2005; Philibin et al., 2009). The mixed
5HT2A/2B/2C antagonist ritanserin did not substitute for clozapine in the present study and
the selective 5-HT2A antagonist M100907 only engendered partial substitution for
clozapine. These data suggest that antagonism of 5-HT2 receptors is not as important for
the discriminative stimulus properties of clozapine in 129S2 mice as it is in C57BL/6
mice. While M100907 has not been tested in DBA/2 mice, the mixed 5HT2A/2B/2C
antagonist ritanserin did not substitute (maximal clozapine drug lever responding of only
18.49%) and examination of individual animal data showed that no mice displayed partial
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substitution (>60% drug lever responding) (Porter et al., 2008) further supporting the idea
that for DBA/2 and 129S2 mice, antagonism of 5-HT receptors is not important for
clozapine‘s discriminative cue.
Cholinergic Muscarinic Antagonism
The muscarinic antagonist scopolamine produced partial substation for clozapine
in the 129S2 inbred strain. While partial substitution with scopolamine was evident in
both C57 and DBA mice, partial substation for clozapine in 129S2 mice was not seen
until a much higher dose of scopolamine (8.0 mg/kg) was tested (as compared to 2.0
mg/kg and 1.0 mg/kg respectively in the C57 and DBA mice). Ki binding data (See table
2) for iloperidone and ziprasidone shows a relatively weak affinity for muscarinic
receptors and their substitution for clozapine coupled with the inability of the selective
muscarinic antagonist scopolamine to substitute suggests that antagonism of muscarinic
receptors does not play an important role in the discriminative cue of clozapine in 129S2
mice.
Alpha Adrenergic Antagonism
The selective alpha adrenergic antagonist prazosin produced full substitution for
clozapine although, like scopolamine, the dose that engendered full substitution in 129S2
mice (10.0 mg/kg) was much higher than the dose that fully substituted for clozapine in
C57BL/6 mice (2.8 mg/kg) (Philibin et al., 2009). Ki values (see table 2) for iloperidone
reveal a stronger binding affinity for alpha adrenergic receptors than for ziprasidone
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Table 2.
Dissociation rate constants for typical and atypical antipsychotic drugs
Dissociation Rate Constants (Ki, nM) are shown for antipsychotic drugs at selected neurotransmitter receptor subtypes (from Schotte et al.
1996 except where indicated). These values should be used for general comparisons only since the species, conditions, tissues and assays
varied among the studies.
Species (except where indicated):

RAT

Tissue (except where indicated): Frontal Cortex
ATYPICAL APDs

5-HT2A

Clozapine
Olanzapine
Ziprasidone
Iloperidone1
Aripiprazole2

3.3
1.9
0.31
0.2
8.7

RAT

RAT

RAT

Striatum

Striatum

Total Cortex

D2

M

150.0
17.0
9.7
3.3
3.3

34
26
5,000
6,000
6,780 (M1)

1
23.0
60.0
12.0
0.31
25.7 (α1A)

GUINEA
PIG
Cerebellum
H1__ _____
2.1
3.5
110.0
12.3
25.1

TYPICAL APDs________________________________________________________________________________
Haloperidol
25.0
1.4
4,670
19.0
730.0
Chlorpromazine
3.35
1.26
3787
14.07
9.04
Thioridazine
6.36
7.96
184
5.04
16.04
5-HT2A = serotonin 5-HT2A receptors; D2 = dopamine D2 receptors; M = cholinergic muscarinic receptors; α1 = α1-adrenoceptors, H1 =
histamine H1 receptors; Ki = equilibrium dissociation constant of the competitive inhibitor; KD = dissociation equilibrium constant
1

Richelson and Souder 2000 (human brain, KD); 2Shapiro et al. 2003 (human cloned); 4Richelson and Nelson 1984 (human brain, KD);
5
Leysen et al.. 1982 (rat cortex); 6Roth et al. 1995 (rat brain); 7Hals et al. 1986 (rat brain);
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suggesting that antagonism of these receptors may be responsible, at least in part, for
clozapine‘s discriminative stimulus properties in 129S2 mice.
Training Dose
The ED50 values for all drugs that produced full substitution for clozapine were
lower in 129S2 mice than C57 and DBA mice (see table 3). The most obvious
explanation for this finding is the lower clozapine training dose used in the 129 mice, as
decreased training dose has been shown to lower ED50 values for substituting drugs
(Stolerman, Childs, Ford, & Grant, 2011). The ED50 values for the atypical antipsychotics
that fully substituted for clozapine (clozapine, olanzapine, and iloperidone) were roughly
half the ED50 values for those drugs than what was seen in the C57 and DBA mice
(iloperidone was not tested in DBA mice). An interesting contrast to this idea, however,
lies in the drugs that did not fully substitute for clozapine.
All three strains of mice showed partial substitution for scopolamine although
129S2 mice did not show substitution until a much higher dose (C57 at 2.0 mg/kg, DBA
at 1.0 mg/kg, and 129 at 8.0 mg/kg). One possible explanation for this increased dose for
drugs substituting for clozapine may be receptor expression; however with little to no
published articles on receptor population or expression in 129S2 mice inferences from
behavioral data must be made. Scopolamine is known to disrupt attention in the FiveChoice Serial Reaction Time Test (5CSRTT) as well as increase omissions and response
latency at higher doses. However, scopolamine produces lower response latencies and a
lower number of omissions in 5CSRTT in 129S2 mice than in DBA and C57 mice,
suggesting that 129S2 mice are less sensitive to the cognitive disruption that scopolamine
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produces in the task (Pattij et al., 2007). It has also been shown that M1 receptor knockout mice (M1R -/-) have a hyperactive phenotype as compared to their wild type
littermates (Miyakawa, Yamada, Duttaroy, & Wess, 2001). In our lab 129S2 mice
displayed significantly lower level of locomotor activity compared to C57, DBA, and
Balb/c inbred mouse strains (unpublished data) and Rogers et al. (1999) reported
hypoactivity in 129 mice as compared to C57 and DBA. These findings imply that M1
receptor expression in 129S2 may be higher than the C57 and DBA inbred strains; this
could also help to explain why 129 mice in the present study were not as susceptible to
scopolamine‘s rate suppressant effects.
The only atypical antipsychotic with discordant substitution and levels of rate
suppression between the three strains was ziprasidone. Both DBA and C57 produced
significant rate suppression at 2.0 mg/kg scopolamine while 129S2 mice were tested up
to 8.0 mg/kg without any significant rate suppression. C57BL/6 mice showed full
substitution for clozapine with ziprasidone while DBA/2 mice produced partial
substitution and 129S/2 mice did not substitute (See Table 3). Ziprasidone‘s diverse
binding profile makes it harder to pinpoint exactly why this is although Ki data suggest a
weaker affinity for muscarinic and H1 histaminergic receptors (as compared to atypical
antipsychotics that substitute for clozapine) that may play a role in this discordant
substitution and rate suppression profile.
Interspecies/Intraspecies Comparisons
While differences in clozapine‘s discriminative stimulus properties between species have
been established, differences within species and between strains may tell us
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Table 3. Comparison of 129S2, C57BL/6, and DBA/2 substitution and generalization tests in clozapine drug discrimination
Results of generalization and substitution testing in C57BL/6, DBA/2, and 129S2/Hsv mice trained to discriminate clozapine from
vehicle in two-lever drug discrimination from the present study, Philibin et al (2005), Philibin et al (2009), and Porter et al (2008).
ED50 values are shown for those drugs that fully substituted for clozapine (i.e. > 80% clozapine-lever responding; dashes indicate that
the drug did not fully substitute for clozapine). The maximum % clozapine-lever responding is shown for all drugs tested. All drugs
were administered s.c.
Drug
ED50 (mg/kg)/Max % DLR ED50 (mg/kg)/Max % DLR ED50 (mg/kg)/Max % DLR
129S2
C57BL/6
DBA/2
Atypical Antipsychotic Drugs
CLOZAPINE
0.50 / 96.8%
1.19 / 97.4%
1.30 / 99.5%
ARIPIPRAZOLE
--- / 44.5%
--- / 41.2%
--- / 37.5%
ILOPERIDONE
0.09 / 84.6%
0.19 / 89.8%
Not Tested
OLANZAPINE
0.04 / 95.6%
0.24 / 87.3%
0.74 / 84.2%
ZIPRASIDONE
--- / 47.9%
0.27 / 93.6%
--- / 62.8%
Typical Antipsychotic Drugs
CHLORPROMAZINE
--- / 72.5%
1.37 / 94.5%
1.51 / 82.0%
HALOPERIDOL
--- / 66.0%
--- / 51.6%
--- / 68.2%
THIORIDAZINE
2.71 / 93.7%
5.85 / 97.5%
6.81 / 90.8%
Selective Ligands
AMPHETAMINE (DA agonist)
--- / 20.5%
--- / 8.1%
--- / 5.5%
M100907 (5-HT2A antagonist)
--- / 69.3%
1.95 / 87.6%
Not Tested
PRAZOSIN (1-adrenoceptor antagonist)
1.14 / 83.4%
1.68 / 92.0%
--- / 20.5%
PYRILAMINE (H1 histaminergic antagonist)
--- / 16.8%
--- / 38.9%
--- / 50.0%
RITANSERIN (5-HT2A/2B/2C antagonist)
--- / 57.4%
2.08 / 94.5%
--- / 18.5%
SCOPOLAMINE (muscarinic antagonist)
--- / 68.0%
--- / 62.3%
--- / 69.2%
Full substitution for clozapine = > 80% clozapine-lever responding
Partial substitution for clozapine = > 60% to < 80% clozapine-lever responding
No substitution for clozapine = < 60% clozapine-lever responding
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more about the importance of different mechanisms for the discriminative stimulus
properties of clozapine and other antipsychotic drugs. While many studies examining
clozapine discrimination with rats report muscarinic antagonism as the main mechanism
of action for the discriminative cue (Goudie et al., 1998; Kelley & Porter, 1997; Millan et
al., 1999) , studies with pigeons and C57BL/6 mice suggest that 5-HT2A antagonism is
important for clozapine‘s discriminative stimulus properties (Hoenicke et al., 1992;
Philibin et al., 2005) and that antagonism of alpha 1 adrenoceptors also plays a role in
clozapine‘s discriminative cue in C57 and 129 mice. Even though the testing of selective
antagonists have suggested neuropharmacological mechanisms that are important for
clozapine‘s discriminative cue, a complete and definitive answer to the underlying
mechanism(s) of action for clozapine discriminative stimulus properties remains elusive
(see reviews by (Goudie & Smith, 1999; Porter & Prus, 2009) and a compound
discriminative cue is the most likely scenario.
The data from (Porter et al., 2008) looking at clozapine discrimination in DBA/2
mice seems to embody this idea of a compound discriminative cue, as none of the
selective ligands tested fully substituted for clozapine. Stolerman and colleges
(Stolerman, Rauch, & Norris, 1987) examined the discriminative stimulus properties of a
compound cue by using a mixture of two pharmacologically independent agents as the
training drug. Rats were trained to discriminate a mixture of 0.2 mg/kg nicotine and 0.4
midazolam. Generalization curves were obtained with both nicotine and midazolam and
each produced high drug lever responding for the compound mixture. While they
reported that each component of the mixture was likely perceived separately, as
antagonism of nicotine and midazalam separately did not block the cue and neither drug
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substituted for the other. However the data from DBA/2 discrimination of clozapine does
not follow this pattern. The drugs used in (Stolerman et al, 1987) were a mixture of
different pharmacological agents, and in that study rats substituted the individual
components of the drug. Clozapine, while having a diverse binding profile, is not
considered a ―mixture‖ of the different receptors antagonists but a single compound
affecting different systems. If clozapine were to be thought of as a ―mixture‖ of different
receptor antagonists then one of the selective antagonists should have produced
substitution. Thus DBA/2‘s discriminative cue is either mediated by a receptor antagonist
that was not tested in the study or it is a complex cue, mediated by a specific mix of
receptor antagonists and not, as Stolerman saw in his rats, parts of a whole.
Training dose of the drug may also change what is important for the
pharmacological mechanisms that mediate clozapine‘s discriminative stimulus. While
antagonism of muscarinic receptors has been shown to be important in rats trained to
discriminate clozapine from vehicle (Goudie et al., 1998; Kelley & Porter, 1997; Nielsen,
1988) a study by Prus, Philibin, Pehrson, and Porter (2006) in which rats trained to
discriminate 5.0 mg/kg and 1.25 mg/kg clozapine from vehicle in a three lever drug
discrimination procedure showed that scopolamine, a muscarinic antagonist, only
produced partial substitution on the 5.0 mg/kg clozapine lever and did not substitute for
clozapine on the 1.25 mg/kg lever. However, if the percent clozapine-lever responding on
both drug levers were combined, scopolamine engendered full substitution for clozapine.
The lack of substitution on a single clozapine dose lever may suggest that the
mechanisms mediating clozapine-like responding may be different between the two
doses. In the present study, the 129S2 mice were trained at a lower training dose than was
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used in previous studies for C57 and DBA mice. This difference in training dose may
account for some of the differences observed between these strains.
Future Studies
Studying the response of inbred strains of mice in the drug discrimination
paradigm helps to establish an important behavioral phenotyping baseline from which we
can compare transgenic and knockout strains. Using knockout mouse strains can help to
further pinpoint the importance of different receptor systems for clozapine‘s
discriminative cue and for other antipsychotic drugs. For example, a 5-HT2A knockout
mouse in a C57BL/6 background could help to determine the importance of 5-HT2A
antagonism in clozapine‘s cue. If 5-HT2A knockout mice are able to be trained to
discriminate clozapine from vehicle that would suggest that alpha adrenergic antagonism
is sufficient for establishing and maintaining clozapine‘s discriminative stimulus in the
absence of 5-HT2A antagonism. Testing other selective ligands as well as other
antipsychotic drugs may also help to identify other putative targets for clozapine‘s
discriminative cue. Examining the phenotypic response to these drugs and further
knowledge of differences in receptor expression between mouse strains can help to
uncover the mechanism(s) of action of antipsychotic drugs and give us further insight to
the neuropharmacological mechanisms for drugs used in the treatment of schizophrenia.
Conclusion
Continued examination of the phenotypic expression of clozapine‘s drug
discrimination can help to determine the neuropharmacological underpinnings of
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antipsychotic drugs and help us to make inferences about the mechanisms of action for
the development of drugs used to treat schizophrenia. Clozapine drug discrimination
continues to be an important preclinical assay for novel antipsychotic drugs that have
similar mechanisms as clozapine and that lack EPS effects. By building on the knowledge
of how both inbred and genetically manipulated mouse strains differ we can also develop
better models to screen and explore the mechanisms of novel antipsychotic drugs as well
as other drugs. While the discriminative stimulus properties of clozapine are robust in
both mice and rats, its relationship to the therapeutic efficacy or adverse side effects of
clozapine remain to be determined.
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